News Articles
Browse our entire archive of news articles, spotlight interviews, and other editorial pieces in one place.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters
Tag
MindMed To Evaluate Ayahuasca’s Active Ingredient DMT In Phase 1 Clinical Trial Collaboration
Mind Medicine (MindMed)
Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health's Advanced Digital Telehealth Platform
Mydecine Innovations Group
Greenstar Biosciences Signs Agreement to Acquire 100 Percent of Eleusian Biosciences Corp.
Lobe Sciences
Dr. Michael Verbora | Field Trip Health
Field Trip Health
New Wave Holdings Corp Appoints Dr. Dennis McKenna to Psychedelic Research Advisory Board
No items found.
Mira X Acquisition Corp. Announces Proposed Qualifying Transaction With Field Trip Psychedelics
Field Trip Health
Headlines | June 12
No items found.
Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out
Braxia Scientific Corp.
Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation
Mydecine Innovations Group
Champignon Announces Closing Of $15 Million Bought Deal Private Placement
Braxia Scientific Corp.
Ben Nikolaevsky | CEO, Pure Extracts
Pure Extracts Corp
Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms
Numinus
Mydecine Innovations Group to Acquire NeuroPharm Inc.
Mydecine Innovations Group
Field Trip Sponsors TheraPsil, a Non-Profit Advocating for Legal, Medically-Supervised, Psilocybin-assisted Psychotherapy
Field Trip Health
NeonMind Expands Development of Psychedelic Patent Portfolio
NeonMind Biosciences Inc.
Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio
Braxia Scientific Corp.
Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients
Mind Medicine (MindMed)
Get the Headlines & Market Updates
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.